Febrile Neutropenia in Children with Cancer: Approach to Diagnosis and Treatment
- 1 January 2018
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pediatric Reviews
- Vol. 14 (3), 204-209
- https://doi.org/10.2174/1573396314666180508121625
Abstract
Background: Febrile neutropenia is one of the major acute side effects of intensive treatment in pediatric cancer, necessitating prompt initiation of empirical broad-spectrum antibiotics. Patients may be classified as low or high risk according some risk factors (duration of neutropenia, depth of neutropenia, type of cancer, state of disease, bone marrow involvement, type of treatment, additional health problems). Initial evaluation of the febrile neutropenic child should include the history of the child, a detailed physical examination, blood culture (peripheral and catheter), urinalysis and culture, cultures of lesions. Result & Conclusion: The standard of care in febrile neutropenic children is that they should be hospitalized, especially if high risk, and should be treated urgently with intravenous wide spectrum empiric antibiotics, the spectrum covering P. Aeruginosa. Empiric treatment should be modified according to culture results and clinical situation. Other options for low risk patients are starting with intravenous treatment and continuing with per oral treatment or giving per oral antibiotic treatment from the beginning.This publication has 27 references indexed in Scilit:
- Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Supportive care in childrenCurrent Opinion in Oncology, 2010
- Geoclimatic Influences on Invasive Aspergillosis after Hematopoietic Stem Cell TransplantationClinical Infectious Diseases, 2010
- Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applicationsAnnals of Oncology, 2010
- Management of febrile neutropenia: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2010
- Risk Factors for Infection-Related Outcomes During Induction Therapy for Childhood Acute Lymphoblastic LeukemiaThe Pediatric Infectious Disease Journal, 2009
- Epidemiology, Outcomes, and Costs of Invasive Aspergillosis in Immunocompromised Children in the United States, 2000PEDIATRICS, 2006
- MONOTHERAPY WITH PIPERACILLIN/TAZOBACTAM VERSUS CEFEPIME AS EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIA IN PEDIATRIC CANCER PATIENTS: A Randomized ComparisonPediatric Hematology and Oncology, 2006
- Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant diseaseCancer, 2003